natgillin/translations-raw huggingface dataset:
The ESPRIT trial used a simplified regimen of heparin during PCI that consisted of an initial bolus of 60 units/kg, with a target ACT of 200 - 300 seconds. 
U studiji ESPRIT koristio se pojednostavljeni režim primjene heparina tijekom PCI koji se sastojao od inicijalnog bolusa od 60 jedinica/kg, s ciljnim ACT od 200 - 300 sekundi.
- if you had a major operation or severe injury during the past 6 weeks. 
− ako ste imali veliki operativni zahvat ili tešku ozljedu tijekom proteklih 6 tjedana.
Before using, the vial contents should be inspected. 
Prije primjene, sadržaj bočice treba pregledati.
What you need to know before you are given Eptifibatide Accord Do not use Eptifibatide Accord: 
Što morate znati prije nego počnete primati Eptifibatid Accord Nemojte primjenjivati Eptifibatid Accord:
- anaemia (decreased number of red blood cells). 
− anemija (smanjeni broj crvenih krvnih stanica).
Compared to placebo, eptifibatide administered as 180/2.0 significantly reduced the incidence of the primary endpoint events (table 1): this represents around 15 events avoided for 1,000 patients treated: 
U usporedbi s placebom, eptifibatid primijenjen u dozi od 180/2,0 značajno je smanjio incidenciju događaja primarne mjere ishoda (Tablica 1), što predstavlja oko 15 izbjegnutih događaja na
The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment. 
Smanjenje incidencije događaja mjere ishoda u bolesnika koji su primali eptifibatid dogodilo se u ranoj fazi liječenja.
Bleeding is most common at the arterial access site in patients undergoing percutaneous arterial procedures. 
Krvarenje je najčešće na mjestu krvožilnog pristupa u bolesnika koji se podvrgavaju perkutanim arterijskim intervencijama.
Because of its short half-life and rapid clearance, the activity of eptifibatide may be halted readily by discontinuing the infusion. 
Zbog kratkog poluvijeka i vrlo brzog klirensa, djelovanje eptifibatida može se brzo zaustaviti prekidanjem infuzije.
What you need to know before you are given Eptifibatide Accord 3. 
Što morate znati prije nego počnete primjati Eptifibatid Accord 3.
It is contraindicated in patients with clinically significant hepatic impairment. 
Kontraindiciran je u bolesnika s klinički značajnim oštećenjem jetrene funkcije.
There was no excessive bleeding in any of these patients, although one patient undergoing CABG surgery was reported as having had a moderate bleed. 
Niti jedan od tih bolesnika nije pretjerano krvario, iako je zabilježeno da je jedan bolesnik koji je imao operaciju ugradnje srčane premosnice umjereno krvario.
Toxicology studies conducted with eptifibatide include single and repeated dose studies in the rat, rabbit and monkey, reproduction studies in the rat and rabbit, in vitro and in vivo genetic toxicity studies, and irritation, hypersensitivity and antigenicity studies. 
Toksikološke studije provedene s eptifibatidom uključuju ispitivanja s pojedinačnim ili ponavljanim dozama na štakorima, kunićima i majmunima, ispitivanja utjecaja na reprodukciju štakora i kunića, in vitro i in vivo ispitivanja genotoksičnosti, te ispitivanja iritacije, preosjetljivosti i antigeničnosti.
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (Dphenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml. 
Mjerenja ADP-om inducirane ex vivo agregacije trombocita pri fiziološkim koncentracijama kalcija (D-fenilalanil-Lprolil-L-arginin klorometil keton antikoagulans) u bolesnika s nestabilnom anginom i infarktom miokarda bez Q-zupca pokazala su inhibiciju ovisnu o koncentraciji s IC50 (50 % inhibitorne koncentracije) od približno 550 ng/ml i IC80 (80 % inhibitorne koncentracije) od približno 1100 ng/ml.
Clinical Trials 
KLINIČKI PODACI
Unlike the approved posology in the EU, the study used a double bolus of study drug (separated by 10 minutes) before the infusion. 
Za razliku od odobrenog načina doziranja u EU, u ovom je ispitivanju korištena primjena dvostrukog bolusa ispitivanog lijeka (u razmaku od 10 minuta) prije kontinuirane infuzije.
GUSTO moderate or severe/life threatening bleeding occurred significantly more often with early routine eptifibatide (7.4 % vs. 5.0 % in delayed provisional eptifibatide group; p <0.001). 
GUSTO umjereno ili jako/životno ugrožavajuće krvarenje se javljalo značajno češće uz ranu rutinsku primjenu eptifibatida (7,4 % naspram 5,0 % pri odgođenoj privremenoj primjeni eptifibatida; p <0,001).
The most common bleeding complications were associated with cardiac invasive procedures (coronary artery bypass grafting (CABG)-related or at femoral artery access site). 
Najčešće su krvarenja kao komplikacije bile povezane s invazivnim kardijalnim procedurama (povezane s ugradnjom premosnice koronarne arterije - CABG ili na mjestu punkcije femoralne arterije).
No genotoxic effects were observed with eptifibatide. 
Nije zabilježena genotoksičnost eptifibatida.
ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with eptifibatide Therapy) was a double-blind, randomised, placebo-controlled trial (n= 2,064) for nonurgent PCI with intracoronary stenting. 
ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with eptifibatide Therapy) je bila dvostruko slijepa, randomizirana, placebom kontrolirana studija (n= 2064) za neurgentne PCI s ugradnjom intrakoronarnog stenta.
There is limited therapeutic experience with eptifibatide in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG). 
Ograničeno je terapijsko iskustvo s eptifibatidom u bolesnika za koje je općenito indicirana trombolitička terapija (npr. akutni transmuralni infarkt miokarda s novim patološkim Q zupcima ili povišenim ST-segmentom ili blokom lijeve grane u EKG-u).
Administration of eptifibatide by intravenous bolus and infusion causes up to a 5-fold increase in bleeding time. 
Davanje eptifibatida intravenskim bolusom i infuzijom uzrokuje produljenje vremena krvarenja do
Before using, inspect the vial contents. 
Prije upotrebe provjerite sadržaj bočice.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: 
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Nositelj odobrenja za stavljanje lijeka u promet:
Cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation. 
Srčani poremećaji Često kardijalni arest, fibrilacija ventrikula, ventrikularna tahikardija, kongestivno zatajenje srca, atrioventrikularni blok, fibrilacija atrija
What Eptifibatide Accord looks like and contents of the pack 
Kako Eptifibatid Accord izgleda i sadržaj pakiranja
This should be taken into consideration by patients on a controlled sodium diet. 
Bolesnici koji su na dijeti s kontroliranim unosom natrija trebaju ovo uzeti u obzir.
− if you have recently had bleeding from your stomach, intestines, bladder or other organs, for example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
− ako ste nedavno imali krvarenje iz želuca, crijeva, mokraćnog mjehura ili drugih organa, na primjer ako ste uočili abnormalnu pojavu krvi u stolici ili mokraći (osim menstrualnog krvarenja) u proteklih 30 dana.
Eptifibatide Accord inhibits platelet aggregation, but does not appear to affect the viability of platelets. 
Eptifibatid Accord inhibira agregaciju trombocita, ali čini se da ne utječe na sposobnost preživljavanja trombocita.
What Eptifibatide Accord is and what it is used for 
Što je Eptifibatid Accord i za što se koristi
Eptifibatide Accord is an antithrombotic agent that acts by inhibition of platelet aggregation; therefore the patient must be observed carefully for indications of bleeding during treatment (see section 4.8). 
Eptifibatid Accord je antitrombotik koji djeluje inhibicijom agregacije trombocita; stoga bolesnika treba pomno nadzirati zbog naznaka krvarenja tijekom liječenja (vidjeti dio 4.8.).
Solution for infusion 100 ml 
Otopina za infuziju 100 ml
The need for blood transfusions was increased modestly by eptifibatide treatment (11.8 % versus 9.3 % for placebo). 
Liječenje eptifibatidom neznatno je povećalo potrebu za transfuzijom krvi (11,8 % prema 9,3 % za placebo).
The primary endpoint of the trial was death (D), MI, urgent target vessel revascularisation (UTVR), and acute antithrombotic rescue with GP IIb/IIIa inhibitor therapy (RT) within 48 hours of randomisation. 
Primarna mjera ishoda ispitivanja bila je smrt, infarkt miokarda, hitna revaskularizacija ciljne krvne žile (UTVR) i akutna antitrombotska hitna intervencija inhibitorom GP IIb/IIIa (RT) unutar 48 sati od randomizacije.
Patients most likely to benefit from eptifibatide treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina. 
Bolesnici kojima će eptifibatid vjerojatno najviše koristiti su oni pod visokim rizikom od razvoja infarkta miokarda unutar prva 3-4 dana nakon nastupa akutne angine.
MI was identified per the CK-MB core laboratory criteria. 
Infarkt miokarda određivao se prema CK-MB osnovnim laboratorijskim kriterijima.
In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of eptifibatide -treated patients vs. 4.6 % of placebo-treated patients. 
U podskupini bolesnika koji su išli na PCI, veliko krvarenje zabilježeno je često, u 9,7 % bolesnika liječenih eptifibatidom naspram 4,6 % bolesnika koji su primali placebo.
Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes. 
Eptifibatid Accord je indiciran za sprječavanje ranog infarkta miokarda u odraslih osoba koji imaju nestabilnu anginu ili infarkt miokarda bez Q-zupca, u kojih se posljednja epizoda boli u prsima dogodila u posljednja 24 sata i koji imaju promjene u elektrokardiogramu (EKG) i/ili povišene srčane enzime.
On the day of PCI, prior to catheterization, 53.2 % received a thienopyridine (clopidogrel 52.7 %; ticlopidine 0.5 %) - mostly as a loading dose (300 mg or more). 
Na dan PCI, prije kateterizacije, 53,2 % bolesnika dobilo je tienopiridin (klopidogrel 52,7 %; tiklopidin 0,5 %) - većinom kao udarnu dozu (300 mg ili više).
After removal of the introducer sheath, careful haemostasis must be ensured under close observation. 
Nakon vađenja uvodnice treba osigurati dobru hemostazu i pomno je nadzirati.
− serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs) 
− ozbiljno krvarenje (na primjer krvarenje u trbušnoj šupljini, u mozgu i u pluća).
319, Pinner Road, Harrow Middlesex HA1 4HF United Kingdom 
319, Pinner Road, Harrow Middlesex HA1 4HF Ujedinjeno Kraljevstvo
It is not known whether eptifibatide is excreted in human milk. 
Nije poznato izlučuje li se eptifibatid u majčino mlijeko.
If the patient requires semi-elective surgery, stop the eptifibatide infusion at an appropriate time to allow time for platelet function to return towards normal. 
Ako je bolesniku potrebna poluelektivna operacija, infuziju eptifibatida treba prekinuti dovoljno rano da se funkcija trombocita vrati na normalnu.
Eptifibatide and thrombolytic agents 
Eptifibatid i trombolitici
− minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding with surgical procedures). 
− manja ili velika krvarenja (npr. krv u mokraći, krv u stolici, krv u povraćenom sadržaju ili krvarenje pri kirurškom zahvatu).
If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period. 
Ako dojite, potrebno je prekinuti dojenje tijekom perioda liječenja.
However, treatment with eptifibatide was associated with antibodies that recognise GPIIb/IIIa occupied by eptifibatide, suggesting an immune-mediated mechanism. 
Naime, liječenje eptifibatidom je bilo povezano s pojavom antitijela koja prepoznaju GPIIb/IIIa receptore koje je zaposjeo eptifibatid, što upućuje na imunološki posredovan mehanizam.
Before infusion of Eptifibatide Accord, the following laboratory tests are recommended to identify preexisting haemostatic abnormalities: prothrombin time (PT) and aPTT, serum creatinine, platelet count, haemoglobin and haematocrit levels. 
Prije infuzije Eptifibatid Accorda, preporučuju se sljedeći laboratorijski testovi u cilju otkrivanja postojećih hemostatskih poremećaja: protrombinsko vrijeme (PV) i aPTT, serumski kreatinin, broj trombocita, razina hemoglobina i hematokrita.
− The active substance is eptifibatide. 
Djelatna tvar je eptifibatid.
Any unused medicine after opening should be thrown away. 
Nakon otvaranja, neupotrijebljeni lijek treba odbaciti.
Physical and chemical compatibility testing indicate that Eptifibatide Accord may be administered through an intravenous line with atropine sulfate, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, tissue plasminogen activator, or verapamil. 
Ispitivanje fizikalne i kemijske kompatibilnosti pokazuje da se Eptifibatid Accord može primijeniti intravenskom linijom zajedno s atropin sulfatom, dobutaminom, heparinom, lidokainom, meperidinom, metoprololom, midazolamom, morfinom, nitroglicerinom, aktivatorom tkivnog plazminogena ili verapamilom.
For a particular adverse reaction, if data was available from both PURSUIT and ESPRIT, then the highest reported incidence was used to assign adverse reaction frequency. 
Za pojedine nuspojave, ako su podaci bili dostupni i iz PURSUIT i ESPRIT ispitivanja, za procjenu učestalosti nuspojave korištena je najviša prijavljena incidencija.
Eptifibatide Accord is also intended for concurrent use with acetylsalicylic acid, as it is part of standard management of patients with acute coronary syndromes, unless its use is contraindicated. 
Eptifibatid Accord je također namijenjen za istodobnu primjenu s acetilsalicilatnom kiselinom (ASK) budući da je dio standardnog načina zbrinjavanja bolesnika s akutnim koronarnim sindromima, ukoliko njegova primjena nije kontraindicirana.
The effect of eptifibatide is observed immediately after administration of a 180 microgram/kg intravenous bolus. 
Učinak eptifibatida primijećen je neposredno nakon primjene 180 mikrograma/kg u intravenskom bolusu.
Unfractionated heparin was administered intravenously or subcutaneously at the physician's discretion, most commonly as an intravenous bolus of 5,000 U followed by a continuous infusion of 1,000 U/h. 
Nefrakcionirani heparin je primijenjen intravenski ili supkutano prema odluci liječnika, najčešće u obliku intravenskog bolusa od 5000 jedinica, te potom kontinuirane infuzije 1000 jedinica na sat.
If the patient weighs < 70 kg, a bolus dose of 60 units/kg is recommended, followed by an infusion of 12 units/kg/hr. 
Ako bolesnik ima < 70 kg, preporuča se doza od 60 jedinica/kg u bolusu, nakon koje treba uslijediti infuzija od 12 jedinica/kg/h.
The activated partial thromboplastin time (aPTT) must be monitored in order to maintain a value between 50 and 70 seconds, above 70 seconds there may be an increased risk of bleeding. 
Valja pratiti aktivirano parcijalno tromboplastinsko vrijeme (aPTT) da bi se održala vrijednost između 50 i 70 sekundi.
Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding. 
Nema pokazatelja da su bolesnici liječeni eptifibatidom, a imali su protrombinsko vrijeme (PV) > 14,5 sekundi i istodobno primali varfarin, bili izloženi većem riziku od krvarenja.
During use of Eptifibatide Accord, you will be checked carefully for any signs of unusual or unexpected bleeding. 
Tijekom primjene Eptifibatid Accorda, posebna pažnja bit će usmjerena uočavanju bilo kakvih znakova neuobičajenog i neočekivanog krvarenja.
Eptifibatide Accord is an inhibitor of platelet aggregation. 
Eptifibatid Accord je inhibitor agregacije trombocita.
Before and during your treatment with Eptifibatide Accord, samples of your blood will be tested as a safety measure to limit the possibility of unexpected bleeding. 
Prije i tijekom liječenja s Eptifibatid Accordom, kao mjera sigurnosti služi provjera uzoraka Vaše krvi, kako bi se smanjila mogućnost neočekivanog krvarenja.
Major bleeding was also very common and reported more frequently with eptifibatide than with placebo in the PURSUIT study (> 1/10 or 10.8 % versus 9.3 %), but it was infrequent in the vast majority of patients who did not undergo CABG within 30 days of inclusion in the study. 
Veliko krvarenje bilo je također vrlo često, a zabilježeno je češće u bolesnika liječenih eptifibatidom nego onih koji su primali placebo u PURSUIT ispitivanju (>1/10 ili 10,8 % prema 9,3 %), no bilo je manje često zabilježeno u većini bolesnika koji nisu bili podvrgnuti CABG-u unutar 30 dana od uključenja u ispitivanje.
Early routine eptifibatide in this high-risk NSTE-ACS optimally-treated population who were managed with an invasive strategy did not result in a statistically significant reduction in the composite primary endpoint of rate of death, MI, RI-UR, and TBO within 96 hours compared with a regimen of delayed provisional eptifibatide (9.3 % in early eptifibatide patients vs. 10.0 % in patients assigned to delayed provisional eptifibatide; odds ratio=0.920; 95 % CI=0.802-1.055; p=0.234). 
Rana rutinska primjena eptifibatida u ovoj populaciji visokorizičnih, optimalno liječenih NSTE ACS bolesnika koji su liječeni i invazivnim metodama, nije rezultirala statistički značajnim smanjenjem združenog primarnog ishoda ispitivanja - stopa smrti, infarkta miokarda, RI-UR i 'bail-out' trombolize tijekom 96 sati, u usporedbi s režimom odgođene privremene primjene eptifibatida (9,3 % u bolesnika s ranom primjenom eptifibatida vs 10,0 % u bolesnika s odgođenom privremenom primjenom eptifibatida; omjer vjerojatnosti = 0,920; 95% CI = 0,802 - 1,055; p=0,234).
No apparent differences were observed between patients treated with eptifibatide or with placebo in values for liver function (SGOT/AST, SGPT/ALT, bilirubin, alkaline phosphatase) or renal function (serum creatinine, blood urea nitrogen). 
Između bolesnika koji su dobivali eptifibatid ili placebo nisu uočene vidljive razlike u vrijednostima pretraga jetrene funkcije (SGOT/AST, SGPT/ALT, bilirubin, alkalna fosfataza) ili bubrežne funkcije (serumski kreatinin, ureja u krvi).
These studies revealed no evidence of impaired fertility or harm to the foetus due to eptifibatide. 
Ova ispitivanja nisu dokazala da je reproduktivna sposobnost narušena ili da je fetus oštećen zbog davanja eptifibatida.
Eptifibatide Accord is given into the vein by direct injection followed by an infusion (drip solution). 
Eptifibatid Accord se daje u venu direktnom injekcijom nakon koje slijedi infuzija (drip otopina).
EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome) was a study of early routine eptifibatide versus placebo (with delayed provisional use of eptifibatide in the catheterization laboratory) used in combination with antithrombotic therapies (ASA, UFH, bivalirudin, fondaparinux or low molecular weight heparin), in subjects with high-risk NSTE ACS. 
Ispitivanje pod nazivom EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome) je bilo ispitivanje rane rutinske primjene eptifibatida u odnosu na placebo, (s odgođenom privremenom upotrebom eptifibatida u laboratoriju za kateterizaciju), primijenjenog u kombinaciji s antitrombotičkim lijekovima (ASK, nefrakcionirani heparin, bivalirudin, fondaparinuks ili niskomolekularni heparin), u visokorizičnih NSTE ACS bolesnika.
Therefore, it is not recommended to administer eptifibatide in patients who have previously experienced immune mediated thrombocytopenia with GP IIb/IIIa inhibitors, including eptifibatide. 
Prema tome, ne preporuča se primjena eptifibatida u bolesnika koji su već doživjeli imunološki posredovanu trombocitopeniju nakon primjene GP IIb/IIIa inhibitora, uključujući eptifibatid.
Eptifibatide Accord is chemically and physically compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride up to 92 hours when stored at 20-25°C. 
Eptifibatid Accord je kemijski i fizikalno kompatibilan s 0,9 %- tnom otopinom natrijevog klorida za infuziju i 5 %- tnom glukozom u Normosolu R, s ili bez kalijevog klorida do 92 sata kada se čuva na temperaturi od 20-25 °C.
If either a confirmed platelet decrease to < 100,000/mm3 or acute profound thrombocytopenia is observed, discontinuation of each treatment medication having known or suspected thrombocytopenic effects, including eptifibatide, heparin and clopidogrel, should be considered immediately. 
Ako se utvrdi pad broja trombocita na < 100 000/mm3 ili akutno nastala teška trombocitopenija, treba odmah razmotriti prekid primjene svih lijekova za koje se zna ili za koje se sumnja da mogu imati trombocitopenični učinak, uključujući eptifibatid, heparin i klopidogrel.
This increase is readily reversible upon discontinuation of the infusion with bleeding times returning towards baseline in approximately 6 (2-8) hours. 
Produljenje se brzo normalizira po prestanku infuzije, a vrijeme krvarenja vraća se prema polaznoj vrijednosti za oko 6 sati (2-8 h).
Similar results were also obtained for the 2 secondary endpoints assessed at 30 days: a triple composite of death, MI and UTVR, and the more robust combination of death and MI. 
Slični rezultati dobiveni su i za 2 sekundarne mjere ishoda procjenjivane nakon 30 dana: kompozitna mjera sastavljena od tri komponente: smrti, infarkta miokarda i hitne revaskularizacije ciljne krvne žile te robustnija kombinacija smrti i infarkta.
Eptifibatide Accord is not usually recommended for use during pregnancy. 
Primjena Eptifibatid Accorda u trudnoći se obično ne preporučuje.
- if you have or have had severe hypertension (high blood pressure). 
− ako ste imali ili imate tešku hipertenziju (visoki krvni tlak)
These may affect more than 1 in 10 people 
Mogu se javiti u više od 1 na 10 osoba
Talk to your doctor or hospital pharmacist or nurse before using Eptifibatide Accord. 
Obratite se svom liječniku ili bolničkom ljekarniku ili medicinskoj sestri prije nego primijenite
The incidence of severe or life threatening bleeding events with eptifibatide was 1.9 % compared to 1.1 % with placebo. 
Incidencija teških i po život opasnih krvarenja u bolesnika koji su dobivali eptifibatid bila je 1,9 % u usporedbi s 1,1 % bolesnika koji su dobivali placebo.
If Percutaneous Coronary Intervention (PCI) is performed during eptifibatide therapy, continue the infusion for 20-24 hours post-PCI for an overall maximum duration of therapy of 96 hours. 
Ako se perkutana koronarna intervencija (PCI) provodi za vrijeme terapije eptifibatidom, infuziju treba nastaviti 20 do 24 sata nakon PCI, do ukupnog trajanja terapije od najduže 96 sati.
Eptifibatide appeared to increase the risk of bleeding when administered with streptokinase in an acute myocardial infarction study. 
Čini se, međutim, da je eptifibatid povećao rizik od krvarenja kad se davao sa streptokinazom u istraživanjima na bolesnicima s akutnim infarktom miokarda.
Very rare 
Vrlo rijetke nuspojave
Heparin administration is recommended unless a contraindication (such as a history of thrombocytopenia associated with use of heparin) is present. 
Preporuča se primjena heparina ukoliko za to ne postoje kontraindikacije (kao što je pojava trombocitopenije inducirane heparinom).
Experience in patients with hepatic impairment is very limited. 
Iskustvo primjene u bolesnika s oštećenjem jetre je vrlo ograničeno.